Vitality Watch

Dossier pubmed observational 01-sep-2026
Human cohort, case-control, or epidemiological association

Impact of the Updated Asian Working Group for Sarcopenia 2025 Criteria on the Prevalence and Clinical Characteristics of Sarcopenic Obesity in Older Patients With Heart Failure.

Key claim: The updated AWGS 2025 diagnostic criteria nearly double the identified prevalence of sarcopenic obesity in older patients with heart failure but do not improve mortality risk stratification.

Abstract

BACKGROUND: The Asian Working Group for Sarcopenia (AWGS) updated its diagnostic criteria in 2025 by incorporating body mass index (BMI)-adjusted skeletal muscle mass. This revision may influence the prevalence and clinical interpretation of sarcopenic obesity in heart failure (HF). METHODS AND RESULTS: We conducted a single-center retrospective cohort study of 589 patients aged ≥65 years who were hospitalized for HF. Application of the AWGS 2025 criteria significantly altered classification, increasing the prevalence of sarcopenic obesity from 7.8% to 13.6%. Among the 4 groups defined by sarcopenia (AWGS 2025) and obesity, patients with sarcopenia without obesity had the worst prognosis, whereas those with sarcopenic obesity had preserved survival (log-rank P=0.038). Following the transition from the AWGS 2019 to AWGS 2025 criteria, newly classified patients with sarcopenic obesity were more frequently female and had a higher BMI with preserved height-adjusted muscle mass compared with patients with persistent sarcopenic obesity. Mortality and gait speed were comparable between the persistent and newly classified sarcopenic obesity groups (both P>0.05). The AWGS 2025 sarcopenia-obesity phenotype classification showed no improvement in discrimination or the Akaike information criterion for prognosis compared with the AWGS 2019 classification (both P>0.05). CONCLUSIONS: The AWGS 2025 criteria increase the prevalence of sarcopenic obesity by identifying a distinct phenotype in patients with HF. However, this expanded classification does not improve risk stratification.

Why this matters

[human-observational] In older patients with heart failure, the updated AWGS 2025 criteria identified substantially more sarcopenic obesity without improving mortality risk stratification, separating diagnostic prevalence from prognostic usefulness. [human-observational] This observational comparison highlights how body-size adjustment changes the population labeled sarcopenic obese, without establishing that the additional diagnoses identify people who benefit from a particular exercise protocol.

Source

Link

Briefing card

Impact of the Updated Asian Working Group for Sarcopenia 2025 Criteria on the Prevalence and Clinical Characteristics of Sarcopenic Obesity in Older Patients With Heart Failure.
Stage: observational · pubmed · 01-sep-2026

If you are an older adult with heart failure, BMI adjustment under the updated criteria could change whether you are classified as having sarcopenic obesity, although it did not improve mortality risk prediction in this study.

The updated AWGS 2025 diagnostic criteria nearly double the identified prevalence of sarcopenic obesity in older patients with heart failure but do not improve mortality risk stratification.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1253/circj.CJ-26-0440

build build 880 · 2bcef25 · 2026-11-18